NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) for NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD)
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Appropriations for patients with rare diseases. Food and Drug Administration Appropriations. National Institutes of Health (NIH) Appropriations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHELLE ADAMS | — |
| MELANIE SWICK BUZZELLI | — |
Medicare/Medicaid MMM
Medicare issues impacting patients with rare diseases. Medicare Part D Program. Section 1115 Waivers. Section 1332: State Innovation Waivers. CMS-2019-0100-0562: Medicare and Medicaid Programs: CY 2020 Home Health Prospective Payment System Rate Update; Home Health Value-Based Purchasing Model; Home Health Value-Based Purchasing Model; Home Health Quality Reporting Requirements; and Home Infusion Therapy Requirements. S.J.Res.52: A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Secretary of the Treasury and the Secretary of Health and Human Services relating to "State Relief and Empowerment Waivers".
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHELLE ADAMS | — |
| RACHEL L. SHER | — |
| MELANIE SWICK BUZZELLI | — |
Health Issues HCR
Health issues impacting patients with rare diseases. H.R.4228: Rare disease Advancement, Surveillance Research, and Education (RARE) Act of 2019. Rare Cancer. Step Therapy. H.R.2279/S.2546: Safe Step Act. Newborn Screening. H.R.2507/S.2158: Newborn Screening Saves Lives Reauthorization Act of 2019. H.R.1379/S.560: Ensuring Lasting Smiles Act. Pediatric Research Equity Act (PREA). Biosimilars. Genetic Testing. Clinical Trials. Institutional Review Boards. Medical Devices. Medical Foods. H.R.2501: Medical Nutrition Equity Act of 2019. Public Law No: 111-148: The Patient Protection and Affordable Care Act. S.1895: Lower Health Care Costs Act. Surprise Medical Billing. Dr. Hahn's Confirmation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHELLE ADAMS | — |
| ROSE AVELLINO GALLAGHER | — |
| RACHEL L. SHER | — |
| MELANIE SWICK BUZZELLI | — |
Pharmacy PHA
Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Drug Pricing. H.R.3: Elijah E. Cummings Lower Drug Costs Now Act. FDA Patient-Focused Drug Development (PFDD) Draft Guidance. H.R.4712: Fairness in Orphan Drug Exclusivity Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHELLE ADAMS | — |
| ROSE AVELLINO GALLAGHER | — |
| RACHEL L. SHER | — |
| MELANIE SWICK BUZZELLI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.